DNLI — Denali Therapeutics Inc. stock price and chart

Share this page

DNLI

$17.61-3.98%

as of close, Oct 16, 2026

☾ AH $17.61 -3.98%

Denali Therapeutics Inc.Stock · HealthcareRussell 2000 0.1%Nasdaq Composite 0.01%Russell 3000 0.005%US Stock Market 0.005%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

Available history since Dec 14, 2017

VolumeEEEE

20172020202220242026

20.030.040.050.060.070.080.090.0010.0M$17.61

2026-10-16

Price$17.61

MA20$22.54

MA50$20.30

Vol9.7M

What would $1,000 invested in DNLI be worth today? →

DNLI returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $17.61
YTD price return: +6.66%
YTD total return: +6.66%
Next earnings: Nov 5, 2026
Market cap: 2.8B2018-03 1.7B2026-10 2.8B+63.3% over the window
Enterprise value: 2.1B
Shares outstanding: 159.8M2017-12 87.5M2026-06 159.8M+82.7% over the window
52W low: $13.75
52W high: $27.30
From 52W high: -35.49%
From 52W low: +28.07%
52W range: 28%

Volume

Rel volume: 1.24×
30D volume: 1.9M
30D $ vol: 37.3M

Fundamentals

Sales (ttm): 3.6M2016-12 02026-06 3.6M
Sales/share: $0.022017-12 $0.002026-06 $0.02
EPS (ttm): -$2.832018-12 -$0.392026-06 -$2.83+626.7% over the window
FCF (ttm): -437.5M2016-12 -78M2026-06 -437.5M+460.5% over the window
FCF/share: -$2.742017-12 -$0.912026-06 -$2.74+201.1% over the window
Book value/share: $5.222017-12 $5.322026-06 $5.22-1.9% over the window
Net margin: -14191.20%2018-03 -14125.3%2026-06 -14191.2%+0.5% over the window
ROE: -61.24%2017-12 -18.9%2026-06 -61.2%+223.5% over the window
ROA: -44.17%2017-12 -18.1%2026-06 -44.2%+143.8% over the window
Current ratio: 8.372017-12 28.922026-06 8.37-71.1% over the window

Growth (CAGR, ttm) · 10Y

Sales: n/a-78.02%2023-06-30 → 2026-06-30339.7M → 3.6M (-98.9% total)-60.12%2021-06-30 → 2026-06-30357.1M → 3.6M (-99.0% total)n/a
Shares: +9.33%2025-06-30 → 2026-06-30146.2M → 159.8M (+9.3% total)+5.17%2023-06-30 → 2026-06-30137.4M → 159.8M (+16.3% total)+5.62%2021-06-30 → 2026-06-30121.6M → 159.8M (+31.4% total)n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share: n/a-79.10%2023-06-30 → 2026-06-30$2.47 → $0.02 (-99.1% total)-62.24%2021-06-30 → 2026-06-30$2.94 → $0.02 (-99.2% total)n/a
Book value/share: -25.63%2025-06-30 → 2026-06-30$7.02 → $5.22 (-25.6% total)-15.42%2023-06-30 → 2026-06-30$8.64 → $5.22 (-39.5% total)-9.94%2021-06-30 → 2026-06-30$8.82 → $5.22 (-40.8% total)n/a
Price: +5.33%2025-10-16 → 2026-10-16$16.72 → $17.61 (+5.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-5.32%2023-10-16 → 2026-10-16$20.75 → $17.61 (-15.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-17.31%2021-10-15 → 2026-10-16$45.56 → $17.61 (-61.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +5.33%2025-10-16 → 2026-10-16$16.72 → $17.61 (+5.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-5.32%2023-10-16 → 2026-10-16$20.75 → $17.61 (-15.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-17.31%2021-10-15 → 2026-10-16$45.56 → $17.61 (-61.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -6.2×2018-03 -19.532026-10 -5.50-71.8% over the window
Fwd P/E: -8.0×
P/S (ttm)Market cap ÷ TTM revenue.: 781.1×2018-06 2246.862026-10 780.61-65.3% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 3.4×2018-03 3.702026-10 3.37-8.9% over the window
EV/Sales (ttm): 595.7×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: -15.54%2017-12 -4.6%2026-06 -10.6%+130.5% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 159.8M ÷ 146.2M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -9.33%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-9.33%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($2B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -9.33%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($-12.4M) ÷ today's market cap ($2.8B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: -0.44%2017-12 -15.4%2026-06 -0.3%-98.0% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $-12.4M + TTM dividends $0) ÷ today's market cap ($2.8B). Same caveat as the cash buyback yield.: -0.44%2017-12 -15.4%2026-06 -0.3%-98.0% over the window

Vs own 10Y history

P/S: 87th
P/B: 40th

Bar = where today’s multiple sits in DNLI’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-3.98%

-9.46%

-12.21%

-22.53%

YTD

+6.66%

+5.32%

-61.35%

Financial statements

Open full DNLI financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

DNLI — Denali Therapeutics Inc. price, chart and key statistics